Medical examiners and Crimean-Congo hemorrhagic fever contamination risk

Özsoy, Sait; Gökmen, Asude; Ozdemir, Mehtap; Akduman, Barış; Korkusuz, Irfan; Javan, Gulnaz T.

doi:10.1016/j.jflm.2015.08.010

Cited by 7 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCHFV causes severe peripheral circulation viraemia, hemorrhage, and tissue lesions, ultimately resulting in multiorgan failure. It initially replicates in blood, liver, and spleen and then systemically spreads to kidney, brain, and lung (Bente et al, 2010;Akinci et al, 2013;Ozsoy et al, 2015;Haddock et al, 2018). To better understand the differential susceptibilities of cell lines to CCHFV, we summarized tissue origins of the human cell lines used in this study in correlation with the tissue targets for CCHFV infection and respective clinical manifestations.…”

Section: Discussionmentioning

confidence: 99%

“…The aetiological agent CCHF virus (CCHFV) is a highly pathogenic tick-borne virus belonging to the genus Orthonairovirus of family Nairoviridae. CCHF severity and CCHFV infection/exposure in humans have been described based on clinical findings and epidemiological studies (Bente et al, 2013;Ozsoy et al, 2015); however, the molecular mechanism underlying CCHF pathogenesis is not well described. CCHFV may be asymptomatic in animals (Spengler et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential Cell Line Susceptibility to Crimean-Congo Hemorrhagic Fever Virus

Dai

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever (CCHF) is a severe tick-borne viral disease of global concerns due to the increasing incidence and lack of effective treatments. The causative agent, CCHF virus (CCHFV), has been characterized for years; however, its tropism in cell lines of different host and tissue origins remains unclear. This study characterized the susceptibility of 16 human and 6 animal cell lines to CCHFV. Increased viral load and viral nucleoprotein expression, and productive CCHFV replication were detected in human vascular (HUVEC), renal (SW-13 and HEK-293), hepatic (Huh7), and cerebral (U-87 MG) cell lines, which were considered CCHFV-highly permissive cell lines. Renal cell lines derived from monkey and dog could also support CCHFV replication. This study evaluated the susceptibility of different cell lines to CCHFV and identified CCHFV-permissive cell lines. Our findings raise concerns regarding the use of cell lines in ex vivo studies of CCHFV and may have important implications for further fundamental research, which would promote understanding of CCHFV pathogenesis and transmission, as well as benefit designing strategies for disease prevention and control.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Differential Cell Line Susceptibility to Crimean-Congo Hemorrhagic Fever Virus

Dai

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…As such this study did not meet our inclusion criteria. Ozsoy 2015 This was a case series with fewer than 10 participants Papa 2008 This was a single case report Pourahmad 2011 This was a single case report Pshenichnaya 2015 This was a case series with fewer than 10 participants Raoofi 2012 This was a case series with fewer than 10 participants Richards 2015 This was a case series with fewer than 10 participants Sahin 2016 This was a single case report Saluzzo 1985b This was a single case report Schwarz 1995 This was a single case report Scrimgeour 1996 This was a case series with fewer than 10 participants Sefikotullari 2013 This case series reported different outcomes from those in our review Sharifi‐Mood 2008 This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm Sharifi‐Mood 2009 This was an overlapping study reporting the same data as an included study ( Sharifi‐Mood 2006 ) Sharifi‐Mood 2013b This was a quasi‐RCT that did not report on ribavirin compared to supportive care only ‐ all participants received ribavirin with or without corticosteroids Sheikh 2005 This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm Sheikh, 2004 This was a case series with fewer than 10 participants Smego 2004 This was a case series with fewer than 10 participants Suleiman 1980 This was a case series with fewer than 10 participants Sunbul 2016 ...…”

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

Ribavirin for treating Crimean Congo haemorrhagic fever

Johnson

Maayan

Mills

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundCrimean Congo haemorrhagic fever (CCHF) is a tick-borne disease that occurs in parts of Asia, Europe and Africa. Since 2000 the infection has caused epidemics in Turkey, Iran, Russia, Uganda and Pakistan. Good-quality general supportive medical care helps reduce mortality. There is uncertainty and controversy about treating CCHF with the antiviral drug ribavirin.ObjectivesTo assess the effects of ribavirin for treating people with Crimean Congo haemorrhagic fever.Search methodsWe searched the Cochrane Infectious Diseases Group Specialized Register; the Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (OVID); Science Citation Index-Expanded, Social Sciences Citation index, conference proceedings (Web of Science); and CINAHL (EBSCOHost). We also searched the WHO International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for trials in progress. We conducted all searches up to 16 October 2017. We also contacted experts in the field and obtained further studies from these sources.Selection criteriaWe evaluated studies assessing the use of ribavirin in people with suspected or confirmed Crimean Congo haemorrhagic fever. We included randomised control trials (RCTs); non-randomised studies (NRSs) that included more than 10 participants designed as cohort studies with comparators; and case-control studies.Data collection and analysisTwo review authors assessed eligibility, risk of bias, and extracted data. For non-randomized studies we used the ROBINS-I tool to assess risk of bias. The main effects analysis included all studies where we judged the risk of bias to be low, moderate or high. We summarized dichotomous outcomes using risk ratios (RRs) and continuous outcomes using mean differences (MDs), and used meta-analyses where appropriate. We carried out a subsidiary appraisal and analysis of studies with critical risk of bias for the primary outcome, as these are often cited to support using ribavirin.Main resultsFor the main effects analysis, five studies met our inclusion criteria: one RCT with 136 participants and four non-randomized studies with 612 participants. We excluded 18 non-randomized studies with critical risk of bias, where none had attempted to control for confounding.We do not know if ribavirin reduces mortality (1 RCT; RR 1.13, 95% confidence interval (CI) 0.29 to 4.32; 136 participants; very low-certainty evidence; 3 non-randomized studies; RR 0.72, 95% CI 0.41 to 1.28; 549 participants; very low-certainty evidence). We do not know if ribavirin reduces the length of stay in hospital (1 RCT: mean difference (MD) 0.70 days, 95% CI -0.39 to 1.79; 136 participants; and 1 non-randomized study: MD -0.80, 95% CI -2.70 to 1.10; 50 participants; very low-certainty evidence). We do not know if it reduces the risk of patients needing platelet transfusions (1 RCT: RR 1.23, 95% CI 0.77 to 1.96; 136 participants; very low-certainty evidence). For adverse effects (including haemolytic anaemia and a need to discontinue treatment), we do not know whether there is a...

show abstract

“…According to Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report published on June 11, 2004, dengue viruses are accepted in the probable biological terrorism agents [30]. Many infections such as tuberculosis, blastomycosis, coccidioidomycosis, acquired immuno-deficiency syndrome, hepatitis B and C (or non-A, non-B), rabies, tularemia, diphtheria, erysipeloid fever, and some of the viral haemorrhagic fevers are transmitted through direct inoculation during autopsies [3,29]. According to the "Biosafety in Microbiological and Biomedical Laboratories" developed by the American Committee on Arthropod-Borne Viruses (ACAV), the Subcommittee on Arbovirus Laboratory Safety (SALS), the Center for Disease Control and Prevention (CDC) and the National Institute of Health, all dengue viruses are in biohazard group 2.…”

Section: Althoughmentioning

confidence: 99%

“…The Flavivirus genus can be further divided into four categories; the mosquito-borne, tickborne, no-known vector and insect-specific viruses [1,2]. Dengue, Zika, West Nile, Yellow Fever, Japanese Encephalitis, Saint Louis Encephalitis and Murray Walley Encephalitis viruses all belong to the mosquito borne Flavivirus genus [1][2][3][4].…”

mentioning

confidence: 99%

The first fatal dengue virus infection case in Turkey: Autopsy findings

Değirmenci¹,

Akar²,

Özsoy³

et al. 2016

RJLM

View full text Add to dashboard Cite

Dengue is the fastest spreading arboviral infection in the world. It is responsible for about 50 to 200 million infections annually. Turkey is accepted in the World Health Organization European region and dengue is now endemic in all World Health Organization regions except for the European region, but people can travel anywhere in the world and they can catch a disease easily. Approximately 2.5 billion people live in dengue endemic countries; therefore, it may be endemic in Europe as well in the near future. It might be seen with increasing frequency in forensic mortuaries soon. In such a situation, the autopsy staff have to keep dengue virus infections in mind to protect themselves from contamination and to detect the cause of death. A case of a 65-year old Thailand citizen male who died in Turkey is presented. He had skin rashes all over the body. His internal examination revealed, 1900 ml, 1700 ml and 80 ml sero-hemorrhagic fluid in the right chest, left chest and pericardial cavities respectively. The sectional cuts of the lungs showed hemorrhagic fluid leakage. Ecchymosis due to intubation was found in the upper tracheal region. Mesocolon transversum showed hemorrhage as well. Blood test results showed Dengue Virus Immunoglobulin G (IFA) and Immunoglobulin M (IFA) positive, Japanese encephalitis virus Immunoglobulin M (IFA) negative and Immunoglobulin G (IFA) positive.

show abstract

Medical examiners and Crimean-Congo hemorrhagic fever contamination risk

Cited by 7 publications

References 15 publications

Differential Cell Line Susceptibility to Crimean-Congo Hemorrhagic Fever Virus

Differential Cell Line Susceptibility to Crimean-Congo Hemorrhagic Fever Virus

Ribavirin for treating Crimean Congo haemorrhagic fever

The first fatal dengue virus infection case in Turkey: Autopsy findings

Contact Info

Product

Resources

About